Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4105 USD | +0.12% | +2.73% | -6.68% |
May. 16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
Apr. 29 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
Financials (USD)
Sales 2024 * | 115K | Sales 2025 * | 1.78M | Capitalization | 20.89M |
---|---|---|---|---|---|
Net income 2024 * | -24M | Net income 2025 * | -25M | EV / Sales 2024 * | 182 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 11.7 x |
P/E ratio 2024 * |
-0.84
x | P/E ratio 2025 * |
-0.9
x | Employees | 27 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.07% |
Latest transcript on AIM ImmunoTech Inc.
1 day | +0.12% | ||
1 week | +2.73% | ||
Current month | +0.49% | ||
1 month | -2.26% | ||
3 months | +1.36% | ||
6 months | -3.41% | ||
Current year | -6.68% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 22-04-03 |
Chief Tech/Sci/R&D Officer | - | 22-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 23-03-27 |
William Mitchell
CHM | Chairman | 89 | 98-06-30 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 0.4105 | +0.12% | 178,825 |
24-05-21 | 0.41 | -1.18% | 81,232 |
24-05-20 | 0.4149 | +2.95% | 175,278 |
24-05-17 | 0.403 | +3.33% | 277,017 |
24-05-16 | 0.39 | -2.40% | 287,138 |
Delayed Quote Nyse, May 22, 2024 at 04:10 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.68% | 20.89M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-1.02% | 21.97B | |
-5.06% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- AIM Stock